Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
474 GBX | +1.07% | +7.24% | -2.67% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
04-19 | Peel Hunt starts NatWest and Barclays at 'buy' | AN |
Sales 2024 * | 1.84B 2.33B 184B | Sales 2025 * | 1.98B 2.51B 198B | Capitalization | 1.49B 1.88B 149B |
---|---|---|---|---|---|
Net income 2024 * | 64M 81.08M 6.4B | Net income 2025 * | 91M 115M 9.1B | EV / Sales 2024 * | 0.81 x |
Net cash position 2024 * | 3.47M 4.4M 347M | Net cash position 2025 * | 8.03M 10.17M 803M | EV / Sales 2025 * | 0.75 x |
P/E ratio 2024 * |
23.3
x | P/E ratio 2025 * |
15.8
x | Employees | 7,859 |
Yield 2024 * |
5.06% | Yield 2025 * |
6.01% | Free-Float | 94.58% |
Latest transcript on PageGroup plc
1 day | +0.54% | ||
1 week | +7.24% | ||
Current month | +6.23% | ||
1 month | +7.73% | ||
3 months | +6.37% | ||
6 months | +7.05% | ||
Current year | -2.67% |
Managers | Title | Age | Since |
---|---|---|---|
Nicholas Kirk
CEO | Chief Executive Officer | - | 31/12/22 |
Director of Finance/CFO | 52 | 30/06/06 | |
Kaye Maguire
LAW | General Counsel | - | 16/09/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marie Metayer
BRD | Director/Board Member | 64 | 31/08/17 |
Director of Finance/CFO | 52 | 30/06/06 | |
Karen Geary
BRD | Director/Board Member | - | 31/03/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
16/05/24 | 474 | +1.07% | 132 882 |
15/05/24 | 480.2 | +1.39% | 235,110 |
14/05/24 | 473.6 | +0.42% | 763,092 |
13/05/24 | 471.6 | +0.55% | 221,672 |
10/05/24 | 469 | +3.17% | 357,140 |
Delayed Quote London S.E., May 16, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.67% | 1.91B | |
+11.63% | 3.44B | |
-4.30% | 2.08B | |
+20.79% | 704M |
- Stock Market
- Equities
- MPI Stock